| 1373 |
National Cancer Institute |
Html |
en |
Cervical Cancer Screening (PDQ®)–Health Professional Version |
Expert-reviewed information summary about tests used to detect or screen for cervical cancer. |
| Obstet Gynecol | 0.581628 |
| Hysterectomy-corrected cervical cancer | 0.555295 |
| HPV DNA testing | 0.788756 |
| cervical cancer worldwide | 0.552556 |
| American Cancer Society | 0.524538 |
| cervical sample collection | 0.524565 |
| Int J Cancer | 0.522908 |
| cervical screening | 0.611205 |
| cervical neoplasia | 0.571227 |
| cervical screening studies | 0.563298 |
| human papillomavirus dna | 0.532798 |
| mild cervical dysplasia | 0.520991 |
| HPV testing | 0.581414 |
| cervical cancer mortality | 0.721474 |
| cervical cancer screening | 0.742524 |
| CIN | 0.553434 |
| Natl Cancer Inst | 0.615845 |
| cervical cancer | 0.995918 |
| cervical squamous cell | 0.556962 |
| cervical human papillomavirus | 0.547211 |
| HPV DNA arm | 0.52076 |
| cervical cytology cotesting | 0.564531 |
| human papillomavirus | 0.694632 |
| cervical cancer death | 0.561576 |
| high-grade cervical lesions | 0.559164 |
|
| cervical cancer incidence | 0.597514 |
| atypical squamous cells | 0.549121 |
| et al. | 0.515402 |
| women | 0.616944 |
| cervical cytology | 0.628179 |
| cervical cancer detection | 0.553165 |
| PUBMED Abstract | 0.530353 |
| invasive cervical cancer | 0.658472 |
| repeat HPV DNA | 0.513096 |
| cervical screening programmes | 0.542296 |
| conventional cervical smear | 0.513052 |
| primary cervical cancer | 0.570395 |
| abnormal cervical cancer | 0.542326 |
| cervical cancer risks | 0.549122 |
| Abstract | 0.599358 |
| Cervical cancer control | 0.552963 |
| cervical cytologic abnormalities | 0.517315 |
| invasive cervical cancers | 0.51155 |
| cervical intraepithelial neoplasia | 0.648604 |
| hpv dna test | 0.564095 |
| squamous intraepithelial lesions | 0.555418 |
| cervical cytologic | 0.523009 |
| cervical cancer cases | 0.567527 |
| Cervical cancer risk | 0.551241 |
|
CLICK HERE |
| 1389 |
National Cancer Institute |
Html |
en |
Breast Cancer Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of ductal carcinoma in situ, lobular carcinoma in situ, and invasive breast cancer. |
| adjuvant chemotherapy | 0.413465 |
| primary breast cancer | 0.408571 |
| Breast cancer prognosis | 0.425608 |
| MammaPrint breast cancer | 0.413079 |
| breast cancer patient | 0.414699 |
| Engl J Med | 0.524403 |
| Breast Cancer Family | 0.427508 |
| Breast Cancer Linkage | 0.421472 |
| Breast Cancer Cooperative | 0.407872 |
| 15-year breast cancer | 0.406317 |
| her2-positive breast cancer | 0.442543 |
| early-stage breast cancer | 0.442314 |
| Radiat Oncol Biol | 0.416027 |
| triple-negative breast cancer | 0.428166 |
| node-positive breast cancer | 0.499527 |
| breast cancer patients | 0.48801 |
| operable breast cancer | 0.439264 |
| Natl Cancer Inst | 0.634346 |
| benign breast disease | 0.41282 |
| receptor-negative breast cancer | 0.410906 |
| surgical adjuvant breast | 0.46168 |
| -negative breast cancer | 0.425377 |
| breast cancer death | 0.425817 |
| invasive breast cancer | 0.473025 |
| et al. | 0.549932 |
|
| contralateral breast cancer | 0.442652 |
| early breast cancer | 0.60357 |
| early-onset breast cancer | 0.418149 |
| stage breast cancer | 0.414667 |
| lobular breast cancer | 0.425161 |
| age-specific breast cancer | 0.41613 |
| PUBMED Abstract | 0.428161 |
| node-negative breast cancer | 0.45155 |
| T1 breast cancer | 0.412562 |
| breast cancer risk | 0.490957 |
| International Breast Cancer | 0.418134 |
| Abstract | 0.568891 |
| Clin Oncol | 0.680872 |
| Danish Breast Cancer | 0.425148 |
| breast cancer | 0.97463 |
| Oncol Biol Phys | 0.418084 |
| Breast Cancer Trialists | 0.422554 |
| breast cancer mortality | 0.404968 |
| Breast Cancer Study | 0.420746 |
| oestrogen-receptor-positive breast cancer | 0.416419 |
| breast cancer incidence | 0.439577 |
| subsequent breast cancer | 0.429086 |
| advanced breast cancer | 0.411746 |
| Breast Cancer Res | 0.494855 |
|
CLICK HERE |
| 1391 |
National Cancer Institute |
Html |
en |
Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of Wilms tumor. |
| wilms tumors | 0.503727 |
| wilms tumor | 0.905843 |
| Wilms tumor development | 0.5254 |
| Wilms tumor genetics | 0.517912 |
| Wilms Tumor Study-5 | 0.477443 |
| familial Wilms tumour | 0.446601 |
| favorable-histology wilms tumor | 0.511105 |
| stage II Wilms | 0.439212 |
| unilateral Wilms tumor | 0.553115 |
| Wilms tumor patients | 0.529584 |
| favorable histology Wilms | 0.460427 |
| bilateral Wilms patients | 0.460054 |
| Tumor Study Group | 0.595101 |
| contralateral Wilms tumor | 0.495745 |
| Wilms tumor-Aniridia syndrome | 0.439108 |
| preoperative wilms tumor | 0.505524 |
| bilateral wilms tumor | 0.635902 |
| stromal-type Wilms tumor | 0.516983 |
| Wilms tumor surveillance | 0.49553 |
| beckwith-wiedemann syndrome | 0.43423 |
| inoperable Wilms tumor | 0.526248 |
| Group/National Wilms Tumor | 0.47873 |
| Low-risk Wilms Tumor | 0.474612 |
| histology Wilms tumors | 0.433526 |
| Wilms Tumor Study | 0.723902 |
|
| Wilms tumor screening | 0.479856 |
| wilms tumor rupture | 0.501052 |
| et al. | 0.499553 |
| wilms tumor predisposition | 0.521351 |
| histology Wilms tumor | 0.504567 |
| Wilms tumours | 0.453209 |
| COG Wilms tumor | 0.518219 |
| SIOP Wilms Tumor | 0.504401 |
| Wilms tumour | 0.50015 |
| bilateral Wilms tumor. | 0.45063 |
| Pediatr Blood Cancer | 0.440629 |
| wilms tumor suppressor | 0.492641 |
| nonsyndromic Wilms tumor | 0.493832 |
| Metachronous bilateral Wilms | 0.434751 |
| National Wilms Tumor | 0.736085 |
| Med Genet | 0.447601 |
| Abstract | 0.531043 |
| Clin Oncol | 0.453706 |
| familial Wilms tumor. | 0.444435 |
| Wilms tumor locus | 0.521817 |
| Familial Wilms tumor | 0.495658 |
| non-WT1-syndromic Wilms tumor | 0.488494 |
| Wilms Tumor Study-3 | 0.478135 |
| Wilms tumor susceptibility | 0.497583 |
|
CLICK HERE |
| 1528 |
National Cancer Institute |
Html |
en |
Ovarian Low Malignant Potential Tumors Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of ovarian low-malignant potential tumors. |
| currently used treatment | 0.491433 |
| treatment | 0.80031 |
| abnormal cells | 0.591776 |
| cancer treatment | 0.491469 |
| ovaries | 0.553108 |
| abdomen | 0.566902 |
| body cavity | 0.495458 |
| NCI-supported cancer | 0.497228 |
| tissue | 0.516419 |
| cancer cells | 0.493195 |
| body | 0.515176 |
| Cancer Information Service | 0.489344 |
| low malignant potential | 0.507879 |
| PDQ cancer information | 0.620272 |
| clinical trial search | 0.566415 |
| uterus | 0.498028 |
| treatment clinical trials | 0.555055 |
| National Cancer Institute | 0.572253 |
| clinical trials | 0.964888 |
| tumor cells | 0.695966 |
| Treatment Options section | 0.484079 |
| cancer information summary | 0.567078 |
| clinical trial | 0.741404 |
| new treatment | 0.564234 |
|
| disease | 0.554973 |
| malignant potential tumor | 0.900634 |
| new treatments | 0.489278 |
| patients | 0.603036 |
| earlier clinical trials | 0.497766 |
| clinical trials database | 0.496798 |
| peritoneal cavity | 0.517264 |
| Potential Tumors Treatment | 0.491558 |
| treatment clinical trial | 0.511947 |
| PDQ Adult Treatment | 0.504736 |
| NCI PDQ cancer | 0.507801 |
| ovary | 0.536161 |
| cancer clinical trials | 0.578107 |
| tests | 0.498811 |
| stage | 0.7416 |
| malignant potential tumors | 0.621847 |
| fallopian tubes | 0.57444 |
| treatment options | 0.549139 |
| Treatment Editorial Board | 0.533517 |
| cancer information summaries | 0.487894 |
| comprehensive cancer information | 0.488381 |
| cancer | 0.721628 |
| standard treatment | 0.552748 |
|
CLICK HERE |
| 1709 |
National Cancer Institute |
Html |
en |
Genetics of Kidney Cancer (Renal Cell Cancer) (PDQ®)–Health Professional Version |
Hereditary kidney cancer (renal cell cancer) syndromes include von Hippel-Lindau disease, hereditary leiomyomatosis and renal cell cancer, Birt-Hogg-Dubé syndrome, and hereditary papillary renal carcinoma. Learn about the genetics, clinical manifestations, and management of these hereditary cancer syndromes in this expert-reviewed summary. |
| Renal cell cancer | 0.417461 |
| sporadic renal cell | 0.38738 |
| renal pelvis cancer | 0.39949 |
| hereditary renal tumors | 0.379064 |
| renal tumors | 0.424533 |
| solid-enhancing renal masses | 0.375815 |
| marginal renal function. | 0.376092 |
| Hippel-Lindau tumor suppressor | 0.449329 |
| cell renal cell | 0.422508 |
| renal replacement therapy | 0.383629 |
| renal parenchymal sparing | 0.388349 |
| von Hippel-Lindau families | 0.43492 |
| Hippel-Lindau tumour suppressor | 0.410095 |
| von hippel-lindau disease | 0.900395 |
| von hippel-lindau | 0.920724 |
| von Hippel Lindau | 0.387864 |
| advanced von Hippel-Lindau | 0.430231 |
| salvage renal surgery | 0.382297 |
| Hippel-Lindau protein mutants | 0.39948 |
| von Hippel-Lindau ubiquitylation | 0.442871 |
| small renal mass | 0.378802 |
| von Hippel-Lindau gene | 0.462044 |
| et al. | 0.556118 |
| small renal masses | 0.392859 |
| sporadic renal masses | 0.379735 |
|
| renal functional outcomes | 0.377613 |
| papillary renal cell | 0.383702 |
| renal carcinomas | 0.373668 |
| renal tubules | 0.373542 |
| hereditary renal cancer | 0.400308 |
| renal disease | 0.379225 |
| ocular von Hippel-Lindau | 0.464552 |
| renal medulla | 0.3796 |
| VHL | 0.386773 |
| von Hippel-Lindau tumor | 0.479006 |
| tumor suppressor gene | 0.380161 |
| Bilateral renal cell | 0.380325 |
| Abstract | 0.55535 |
| Hippel-Lindau disease tumor | 0.448931 |
| von Hippel-Lindau patients | 0.465787 |
| sporadic renal carcinoma. | 0.386645 |
| renal cell carcinoma | 0.660911 |
| Hippel-Lindau gene mutations | 0.398567 |
| Hippel-Lindau protein promotes | 0.402255 |
| von Hippel-Lindau protein | 0.50858 |
| von hippel-lindau syndrome | 0.558083 |
| clear-cell renal cell | 0.409767 |
| Hum Genet | 0.372826 |
| von Hippel-Lindau mutation | 0.438746 |
|
CLICK HERE |
| 1837 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de pene (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de pene. |
| Horenblas S | 0.510336 |
| Nielsen OS | 0.509173 |
| Compton CC | 0.557867 |
| therapy with cisplatin | 0.51114 |
| alta incidencia | 0.509039 |
| Russo P | 0.509584 |
| Ta Carcinoma | 0.513251 |
| radical inguinal lymphadenectomy | 0.511322 |
| invasive carcinoma | 0.512611 |
| Urologic Cancer | 0.517007 |
| 7th ed | 0.565184 |
| linfadenectomÃa profiláctica | 0.526988 |
| Radiat Oncol Biol | 0.519915 |
| Verrucous carcinoma | 0.511779 |
| papillomavirus-associated penile squamous | 0.511778 |
| epidermoid carcinoma | 0.511036 |
| retrospective analysis | 0.533675 |
| papillomavirus dna | 0.511396 |
| 8th ed | 0.50889 |
| tÃpico carcinoma | 0.513162 |
| Waters WB | 0.509049 |
| Lindegaard JC | 0.509948 |
| human papillomavirus | 0.555341 |
| Catalona WJ | 0.510454 |
| Javadpour N | 0.50987 |
|
| estadio iv | 0.51387 |
| Neoadjuvant therapy with | 0.511141 |
| Surg Pathol | 0.512914 |
| Microscopically controlled surgery | 0.510476 |
| Perez CA | 0.516876 |
| Reda DJ | 0.508824 |
| Harty JI | 0.510648 |
| Surgical treatment | 0.514704 |
| Cancer Staging Manual | 0.614394 |
| carcinoma with | 0.51364 |
| treatment with | 0.51195 |
| carcinoma basaloide | 0.513292 |
| New York | 0.574898 |
| Lundbeck FA | 0.510525 |
| sentinel node biopsy | 0.508574 |
| Oncol Biol Phys | 0.520345 |
| squamous cell carcinomas | 0.95738 |
| Ornellas AA | 0.50861 |
| Byrd DR | 0.554153 |
| Zhang ZF | 0.510317 |
| treated with | 0.512687 |
| Acta Oncol | 0.509033 |
| Tis Carcinoma | 0.513411 |
| AJCC Cancer Staging | 0.617972 |
|
CLICK HERE |
| 2041 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de vejiga y otros cánceres uroteliales (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca de las pruebas que se usan para detectar sistemáticamente el cáncer de vejiga. |
| antecedentes familiares | 0.40081 |
| Schistosoma haematobium | 0.417111 |
| Visuals Online | 0.357081 |
| PDQ Exámenes | 0.503031 |
| Physician Data Query | 0.696072 |
| Estados Unidos | 0.406708 |
| túbulos renales | 0.432914 |
| prevención revisa | 0.368302 |
| sistema urinario masculino | 0.518469 |
|
| largo plazo | 0.406946 |
| vejiga almacena | 0.840919 |
| información ayuda | 0.374743 |
| biopsia.ampliar cistoscopia | 0.431465 |
| National Cancer Institute | 0.400139 |
| siguientes riesgos | 0.364163 |
| pelvis renal | 0.934476 |
| Instituto Nacional | 0.483729 |
|
CLICK HERE |
| 3855 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer sin daño al corazón |
Investigadores de los campos de oncología y de cardiología están trabajando para encontrar formas de impedir, manejar y posiblemente aun revertir los efectos secundarios cardiovasculares de ciertas terapias del cáncer. |
| doctora minasian | 0.420648 |
| Toxicidad Cardiovascular | 0.397361 |
| funciones cardÃacas | 0.389495 |
| oncologÃa comunitaria suncoast | 0.499346 |
| Estudio PREDICT | 0.431531 |
| doctores edward t.h | 0.46464 |
| Eileen Dimond | 0.383363 |
| Más gente | 0.39382 |
| Cancer Center | 0.835847 |
| Instituto Nacional | 0.378255 |
| evento coronario | 0.384904 |
| necesaria investigación | 0.396051 |
| Gregory Hundley | 0.381508 |
| uso del lisinopril | 0.382252 |
| NCI.“El NCI | 0.483538 |
| mayores aumentos | 0.393722 |
| bloqueador beta | 0.384896 |
| cuestión provocativa número | 0.450757 |
| alto riesgo | 0.61435 |
| doctor saro armenian | 0.462785 |
| Mayo Clinic | 0.37936 |
| enfermedad isquémica cardÃaca | 0.538111 |
| carvedilol fosfato | 0.395021 |
| Anderson Cancer Center | 0.780116 |
|
| editorial anexo | 0.379604 |
| Dana-Farber Cancer Institute | 0.454758 |
| Brigada Comunitaria | 0.385219 |
| efectos tardÃos | 0.687242 |
| Pimprapa Vejpongsa | 0.386075 |
| Wake Forest Baptist | 0.436151 |
| doctor gregory t | 0.449856 |
| futuras investigaciones | 0.386679 |
| efectos secundarios cardÃacos.Sustancias | 0.621707 |
| MD Anderson Cancer | 0.78917 |
| médicos oncólogos | 0.393733 |
| supervivientes adultos | 0.958505 |
| cardiopatÃa coronaria | 0.411854 |
| Jude Children´s Research | 0.445325 |
| corto plazo | 0.380257 |
| Vanderbilt-Ingram Cancer Center | 0.454856 |
| doctora sarah c | 0.467574 |
| doctora pooja p | 0.468177 |
| Estudio USF | 0.426971 |
| doctor javid moslehi | 0.464739 |
| doctor w | 0.384312 |
| largo tiempo | 0.383822 |
| doctora lori minasian | 0.500028 |
| doctor moslehi | 0.395708 |
|
CLICK HERE |
| 14599 |
National Cancer Institute |
Html |
en |
PET-CT–Guided Surveillance May Reduce Need for Surgery in Some Patients with Advanced Head and Neck Cancer |
Patients with advanced squamous cell carcinoma of the head and neck who underwent PET-CT–guided surveillance had fewer operations but similar overall survival rates to those of patients who underwent planned neck dissection. |
| fewer neck dissections | 0.480753 |
| different PET-imaging systems | 0.416156 |
| trial | 0.383529 |
| surgical dissection | 0.49691 |
| surgery group | 0.546725 |
| equivocal response | 0.373027 |
| main goal | 0.370069 |
| standard first-line therapy | 0.446339 |
| 2-year overall survival | 0.421723 |
| results | 0.372041 |
| PET-CT–guided surveillance | 0.384586 |
| PET-CT group | 0.386097 |
| advanced squamous cell | 0.578344 |
| standardized PET imaging | 0.419169 |
| heterogeneous study population | 0.413368 |
| 2,200-per-patient cost savings | 0.413451 |
| study groups | 0.42202 |
| patients | 0.610711 |
| metabolic abnormalities | 0.37096 |
| Dr. Malik | 0.419332 |
| health care costs | 0.414997 |
| lymph nodes | 0.375275 |
| overall survival rates | 0.55552 |
| surveillance group | 0.491325 |
|
| chemoradiation | 0.396529 |
| Shakun Malik | 0.372291 |
| nodal metastases | 0.375714 |
| positron-emission tomography | 0.373068 |
| magnetic resonance imaging | 0.431542 |
| Cancer Research UK | 0.422638 |
| Technology Assessment Programme | 0.42519 |
| United States | 0.41309 |
| N3 disease | 0.374897 |
| fewer operations | 0.382441 |
| randomized controlled PET-NECK | 0.429823 |
| PET-CT imaging | 0.485125 |
| advanced imaging techniques | 0.434786 |
| neck dissection | 0.819668 |
| PET-CT surveillance | 0.497223 |
| neck dissection patients | 0.544115 |
| Hisham Mehanna | 0.370962 |
| long-term results | 0.369928 |
| trial results | 0.371832 |
| United Kingdom | 0.369679 |
| cancer treatment centers | 0.428263 |
| substantial complications | 0.369604 |
| New England Journal | 0.442645 |
| clinical usefulness | 0.371858 |
|
CLICK HERE |
| 15878 |
National Cancer Institute |
Html |
es |
Antineoplastones (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos sobre los antineoplastones como tratamiento para personas con cáncer. |
| with antineoplaston a2 | 0.218822 |
| Investigación Burzynski | 0.22067 |
| with antineoplastons | 0.246694 |
| Exp Clin Res | 0.800411 |
| antineoplastón a10 | 0.397658 |
| Initial clinical study | 0.211468 |
| prostate with antineoplaston | 0.217616 |
| Purified Antineoplaston Fractions | 0.215376 |
| antineoplaston a10 | 0.272621 |
| pacientes nimustina | 0.213052 |
| antineoplastons a10 | 0.222443 |
| Clin Proc | 0.222323 |
| study with antineoplaston | 0.218319 |
| Veinte pacientes | 0.213707 |
| antineoplastón a3 | 0.224113 |
| chemoradiation therapy with | 0.212987 |
| Oncol Rep | 0.240747 |
| Soc Exp Biol | 0.215807 |
| patients with | 0.222048 |
| Physiol Chem Phys | 0.238091 |
| antineoplastones a10 | 0.278317 |
| pacientes respuesta | 0.221956 |
| Burzynski SR | 0.970231 |
| Kubove E | 0.284007 |
| US Patent | 0.217212 |
|
| antineoplaston a10 with | 0.212999 |
| Antineoplaston treatment | 0.211591 |
| patients with five | 0.213355 |
| Arch Pharm Res | 0.21496 |
| Drugs Exp Clin | 0.778727 |
| Kumabe T | 0.215619 |
| Instituto Burzynski | 0.215357 |
| antineoplaston as2-1 | 0.25609 |
| Toxicology studies | 0.237437 |
| antineoplastones a2 | 0.223629 |
| antineoplastón as2-5 | 0.218066 |
| inhibitory effect | 0.218192 |
| Antineoplaston Study Group | 0.215678 |
| antineoplastón as2-1 | 0.256718 |
| clinical study with | 0.213829 |
| antineoplaston as2-5 | 0.211859 |
| Tsuda H | 0.416032 |
| clinical studies | 0.21939 |
| Proc Soc Exp | 0.216295 |
| with five years | 0.211921 |
| Burzynski B | 0.287937 |
| Mohabbat MO | 0.210993 |
| Exp Biol Med | 0.216836 |
| Integr Cancer Ther | 0.216474 |
|
CLICK HERE |